The first half of 2026 reinforces a clear strategic trend: medtech companies are reshaping portfolios to capture faster-growing, technology-driven markets rather than pursuing scale alone.
According to PwC, global medtech M&A reached US$36.5 billion in H1 2026, with deal value and volume remaining above the midpoint of 2025, building on last year’s decade-high transaction activity.
Key strategic themes emerging from the market include:
- Growth over diversification: Companies are prioritizing high-growth segments such as thrombectomy, structural heart, neuromodulation, digital pathology, and intravascular lithotripsy (IVL).
- Portfolio optimization: While acquisitions accelerated, strategic divestitures also gained momentum. Thermo Fisher’s sale of its microbiology business highlights an increasing focus on reallocating capital toward higher-growth platforms.
- Technology-led competitive positioning: Digital diagnostics, AI-enabled pathology, minimally invasive therapies, and precision medicine continue attracting premium valuations.
The largest transactions shaping H1 2026 include:
- Boston Scientific – Penumbra: US$14.5B to strengthen leadership in thrombectomy and embolization.
- Danaher – Masimo: US$9.9B to expand acute-care diagnostics and patient monitoring capabilities.
- Boston Scientific – MiRus: US$1.5B investment with an option to acquire its next-generation TAVR platform.
- American Industrial Partners – Avanos Medical: US$1.27B take-private transaction.
- Thermo Fisher – Microbiology Business: US$1.08B divestiture to Astorg.
- Roche – PathAI: Up to US$1.05B to strengthen AI-powered digital pathology.
- Agilent – Biocare Medical: US$950M to expand cancer diagnostics capabilities.
- Stryker – Amplitude Vascular: Up to US$835M to enter the rapidly growing IVL market.
- Medtronic – SPR Therapeutics: US$650M to enhance neuromodulation for chronic pain.
- Medtronic – CathWorks: US$585M to advance coronary physiology and interventional cardiology.
The broader implication: Medtech leaders are increasingly using M&A as a strategic lever to accelerate innovation, strengthen competitive differentiation, and position themselves in the fastest-growing areas of healthcare. As AI, minimally invasive technologies, and precision diagnostics continue to evolve, portfolio transformation is likely to remain a defining theme across the industry.
For more details reach us at https://www.apeloconsulting.com/reports
Email:Â [email protected]
#MedTech #Healthcare #MedicalDevices #MergersAndAcquisitions #BostonScientific #Medtronic #Danaher #Roche #Agilent #Stryker #ThermoFisher #DigitalPathology #PrecisionMedicine #Diagnostics #HealthcareInnovation #IVD #TopDeals